

Equivalence of the Insulin Sensitivity Index in Man Derived by the Minimal Model Method and the Euglycemic Glucose Clamp

Richard N. Bergman, Rudy Prager, Aage Volund, and Jerrold M. Olefsky

Department of Physiology and Biophysics, University of Southern California School of Medicine, Los Angeles, California 90033; Department of Medicine, University of California, San Diego, and the Veterans Administration Medical Center, San Diego, California 92161

Abstract

Studies were done to determine whether the minimal model approach and the glucose clamp measure equivalent indices of insulin action. Euglycemic glucose clamps (glucose, G: 85 mg/dl) were performed at two rates of insulin (I) infusion (15 and 40 mU/min per m²) in 10 subjects (body mass index, BMI, from 21 to 41 kg/m²). Insulin sensitivity index (S_I) from clamps varied from 0.15 to 3.15 (mean: $1.87 \pm 0.36 \times 10^{-2}$ dl/[min per m²] per μ U/ml), and declined linearly with increasing adiposity (versus BMI: $r = -0.97$; $P < 0.001$). S_I from modeling the modified frequently sampled intravenous tolerance test varied from 0.66 to 7.34×10^{-4} min⁻¹ per μ U/ml, and was strongly correlated with S_{IP(clamp)} ($r = 0.89$; $P < 0.001$). S_I and S_{IP(clamp)} were similar (0.046 ± 0.008 vs. 0.037 ± 0.007 dl/min per μ U/ml, $P > 0.35$); the relation had a slope not different from unity (1.05 $P > 0.70$) and passed through the origin ($P > 0.40$). However, on a paired basis, S_I exceeded S_{IP(clamp)} slightly, due to inhibition of hepatic glucose output during the FSIGT, not included in S_{IP(clamp)}. These methods are equivalent for assessment of overall insulin sensitivity in normal and insulin-resistant nondiabetic subjects.

Introduction

A consensus has emerged that insulin resistance is an important component in the etiology of glucose intolerance in a variety of metabolic conditions, including obesity (1), aging (2), and non-insulin-dependent diabetes mellitus (3). Thus, it is an important goal to be able to quantify the degree of sensitivity of the tissues to insulin as an indication of the prevalence and/or progress of metabolic disease, and to evaluate the effectiveness of specific therapies. In recent years, a variety of approaches have been put forth to yield either qualitative (4) or quantitative indices of in vivo insulin sensitivity (5). Most recently, the euglycemic clamp of Andres and his colleagues has gained widespread use (6).

While the glucose clamp is widely regarded as the "gold standard" for sensitivity measurement, it remains primarily a laboratory procedure, because it requires sophisticated equipment, highly trained personnel, and it is costly and labor inten-

sive. There remains a need for alternative methods for measuring insulin sensitivity which require less experimental sophistication.

The minimal model methodology has been proposed as a simple alternative to the glucose clamp. With this method, the computer is used to calculate insulin sensitivity from the glucose and insulin dynamics observed during the frequently sampled intravenous glucose tolerance test (FSIGT¹; 7-9).

The question has arisen as to the accuracy of the insulin sensitivity index, S_I, which is estimated from minimal model analysis of the FSIGT. Donner and his colleagues (10), and Foley et al. (11) reported a weak, marginally significant correlation between insulin sensitivity determined by the minimal model approach and the euglycemic clamp, although the reason for this lack of correlation was not determined. Beard and his colleagues demonstrated that the correlation between these methods became much stronger ($r = 0.83$) when they utilized a modified FSIGT protocol, which entailed the sequential injection of glucose and tolbutamide (12).

The results of Beard and his colleagues suggest that the minimal model approach is an alternative to the euglycemic clamp, in that acceptable estimates of insulin sensitivity may be obtained from either. However, the attractiveness of the minimal model approach would increase if the sensitivity index derived therein were not just related to the clamp-based index, but if, in fact these independently derived measures were equivalent.

In the present study, we measured the insulin sensitivity index in a group of individuals of varying body weight, using both the euglycemic clamp, and the minimal model method. Our goal was to determine whether the model-based sensitivity index was simply a correlate of insulin sensitivity, or whether application of the minimal model yielded the same measure of insulin sensitivity as the euglycemic clamp method.

Methods

Subjects

10 subjects were studied (Table I; 9 male, 1 female). Body mass indices varied from 21 to 41 kg/m². Thus, 4 subjects were of normal weight, and the remainder were obese. After admission to the Special Diagnosis and Treatment Unit at the San Diego Veterans Administration Hospital, subjects were put on a weight-maintaining diet (32 kCal/kg per d) with the following composition: carbohydrate 45%, protein 15%, fat 40%, served in three portions: $\frac{1}{3}$ at 8 a.m., $\frac{2}{3}$ each at noon and 5 p.m. Each study was performed at least 48 h after admission, beginning at 7 a.m., after an overnight fast. All 10 patients were subjected to one euglycemic clamp study (insulin infusion rate 40 mU/min per m²) and an additional

Address reprint requests to Dr. Bergman. Dr. Prager is on leave from the Second Department of Medicine, University of Vienna, Austria. Dr. Volund is a visiting scientist from the Novo Research Institute, Bagsvaerd, Denmark.

Received for publication 23 April 1986 and in revised form 3 November 1986.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/87/03/0790/11 \$1.00

Volume 79, March 1987, 790-800

1. Abbreviations used in this paper: BMI, body mass index; FSIGT, frequently sampled intravenous glucose tolerance test; GINF, glucose infusion; HGO, hepatic glucose output; R_g, glucose uptake; SA, surface area; S_I, insulin sensitivity index; S_{IP(clamp)}, clamp-derived insulin sensitivity index; V_D, distribution volume.

Table I. Human Subjects

	Age	Sex	Height	Weight	BMI	Surface area
	yr		cm	kg	kg/m ²	m ²
1	28	M	173	74	25	1.87
2	30	M	174	65	21	1.76
3	34	M	170	66	23	1.78
4	37	M	181	76	23	1.98
5	35	M	170	80	28	1.92
6	58	M	178	97	31	2.18
7	53	M	191	120	33	2.47
8	39	M	174	121	40	2.32
9	29	F	160	90	35	1.98
10	38	M	184	140	41	2.58

clamp study (15 mU/min per m²) was also performed on eight of them. In addition, a single tolbutamide-modified FSIGT was performed on each subject. Studies were randomized, and performed on different days. All experimental protocols were approved by the University of California at San Diego (UCSD) and Veterans Administration (VA) Human Subjects Research Review Committee of the UCSD and VA Medical Center. Informed consent was obtained from all subjects.

Glucose clamp studies

Euglycemic glucose clamp studies were conducted as previously described (13). Intracatheters were placed in one antecubital vein and a dorsal hand vein cannulated in the retrograde direction. The hand was kept in a heating pad to provide arterialized venous blood. Labeled glucose (3-[³H]glucose) was injected (60 μCi) and infused (0.6 μCi/min) thereafter for the entire experiment. 60 min after tracer infusion was begun, insulin was infused, continuing for 3 h. During the insulin infusion, glucose was maintained at 85 mg/dl by a variable infusion of 20% dextrose. The infusion was adjusted according to glucose determinations made every 5 min on a glucose analyzer (Yellow Springs Instruments, Yellow Springs, OH). For calculation of insulin sensitivity, we defined glucose infusion rate as steady state by calculating the average rate over the final 40 min of insulin infusion. Additional blood samples for determination of insulin and glucose specific activity were collected every 20 min during the glucose clamp.

FSIGT

After placement of the two intracatheters, four basal samples were collected over 20 min, after which glucose (0.3 g/kg) was injected over 1 min, as described (9). An additional injection of tolbutamide (Orinase i.v., Upjohn, Kalamazoo, MI) was given over 20 s, 20 min after glucose. Subjects with body mass index (BMI) < 30 kg/m² were given 300 mg tolbutamide; subjects with BMI > 30 kg/m² were given 500 mg. These doses were equivalent to 4.19±0.40 mg/kg (SD) for the lower BMI subjects, and 4.52±0.80 mg/kg for the greater BMI subjects (*P* > 0.40). Blood samples (4 ml) were collected at the following times after glucose injection at *t* = 0: 2, 3, 4, 5, 6, 8, 10, 12, 14, 16, 19, 22, 24, 25, 27, 30, 40, 50, 60, 70, 90, 100, 120, 140, 160, and 180 min. Addition of the tolbutamide injection to the glucose injection protocol decreases the coefficient of variation of the estimate of the insulin sensitivity index (S_I) from 32 to 13% (reference 14, assuming a 2% coefficient of variation in the glucose assay).

Analytical methods

Glucose kinetics. Specific activity and glucose data were smoothed using the optimal segments method (15), and glucose appearance and disappearance rates were calculated from the derivative form of the Steele relationship (16). Hepatic glucose output was calculated as the difference between total glucose appearance rate and the rate of glucose infusion. Insulin was measured by double antibody radioimmunoassay (17).

Data analysis and statistics

The insulin sensitivity index was calculated from FSIGT results using the program MINMOD (copyright R. N. Bergman, 1986), which was run on the VAX-750 at the USC Physiology and Biophysics Department (18). This program accepts as input the temporal pattern of plasma insulin during the FSIGT, and must fit a simple (minimal) model of insulin-dependent glucose utilization to the measured glucose pattern. The model is the simplest mathematical representation that can account for the dynamics of glucose during the FSIGT. The equations of the minimal model are as follows (7): $dG(t)/dt = -[p_1 + X(t)]G(t) + p_1G_b$, $dX(t)/dt = -p_2X(t) + p_3I(t)$, where $G(t)$ and $I(t)$ are the plasma glucose and insulin concentrations, $X(t)$ is insulin in a compartment remote from plasma, and p_1 , p_2 , and p_3 are model parameters. G_b and I_b are preinjection glucose and insulin concentrations. Parameter p_1 is the fractional disappearance rate of glucose, at basal insulin, independent of the insulin response. Parameters p_2 and p_3 determine the kinetics of transport into and out of the remote insulin compartment where insulin action is expressed.

Parameters of the model are estimated from least-squares fitting of the glucose data, and the insulin S_I is calculated as the ratio of two of the fitted model parameters (p_3/p_2 , c.f. Appendix of reference 7). In addition, the fitting procedure yields the apparent volume of distribution of glucose (V_D) corresponding to the single compartment of the minimal model, and $S_G (= p_1)$, fractional disappearance rate of glucose independent of the insulin increment. The program MINMOD, adapted for the microcomputer or the VAX computer may be purchased from Dr. R. Bergman.

Standard statistical methods including paired and unpaired *t* tests, linear regression and correlation analysis were used to examine the relationship between measures of insulin sensitivity from the clamp versus the minimal model methods (19).

Results

Glucose clamps. The subjects ranged in BMI from 21 to 41 kg/m² (Table I). Basal glucose production (equals basal uptake) was relatively constant for all individuals when normalized to body surface area (Table II, 79±13 (mean±SD) mg/min per m²; *r* = 0.18 (NS) with BMI) as would be expected for nondiabetic individuals (20). Unlike basal glucose production, there was a wide range of basal insulin levels in these subjects (range, 7 to 46 μU/ml), and basal insulin was correlated with BMI (*r* = 0.81, *P* < 0.01).

Glucose clamps were done at a low [15 mU/(min per m²)] or moderate [40 mU/(min per m²)] insulin infusion rate. Steady state insulin levels attained were 41±4 and 114±6 μU/ml at the two rates, respectively (mean±SE, Table II). Glucose uptake (R_d) during the 140–180-min period varied among subjects from 68 to 156 mg/min per m² at the lower infusion rate; at the higher rate the range was 90 to 340 mg/min per m². Glucose uptake at either infusion rate was reduced as BMI increased (correlation with BMI, *r* = -0.84 and -0.90 at the low and moderate rates of insulin infusion).

We have previously defined the insulin sensitivity index for the euglycemic glucose clamp, $S_{IP(\text{clamp})}$, as the steady state ratio of the increment in glucose uptake (ΔR_d) to the increment in plasma insulin concentration (ΔI), normalized to the ambient plasma glucose concentration (G) at which the clamp is performed (5): $S_{IP(\text{clamp})} = \Delta R_d / (\Delta I \times G)$.

In the present studies, we obtained values of plasma insulin and R_d at basal, as well as during the low and moderate dose insulin infusions (Table II). Thus, $S_{IP(\text{clamp})}$ could be calculated using the increments in insulin and R_d between any two of these three sets (i.e., basal to 15, 15 to 40, or basal to 40 mU/min per

Table II. Euglycemic Clamp Results

Subject	Basal		Low insulin		Intermediate insulin		$S_{IP(\text{clamp})}$ $\times 10^2 \text{ dl}/(\text{min} \cdot \text{m}^2)$ per $\mu\text{U}/\text{ml}$
	Insulin*	R_d	Insulin	R_d	Insulin	R_d	
			15 mU/m ² · min		40 mU/min · m ²		
1	16	76	51	150	102	277	2.75
2	9	90	45	149	112	340	2.86
3	8	65	35	132	108	328	3.09
4	8	55	31	129	76	237	3.15
5	7	95	38	156	102	284	2.34
6	10	90	33	87	118	235	1.58
7	4	79	27	83	141	265	1.72
8	43	78	—	—	133	90	0.15
9	12	81	—	—	109	135	0.66
10	46	77	64	68	138	106	0.36
Mean±SE	17±5	79±4	41±4	119±12	114±6	230±28	1.87±0.36
Correlation $r =$ with BMI	0.81 ($P < 0.01$)	0.18 (NS)		-0.84 ($P < 0.01$)		-0.90 ($P < 0.001$)	-0.97 ($P < 0.001$)

* Insulin concentration is expressed in $\mu\text{U}/\text{ml}$; R_d is expressed in mg/min per m^2 .

m^2). As an alternative, we could utilize the slope of the best-fit linear regression of steady state R_d on steady state plasma insulin, employing all three data sets (basal, 15 and 40 mU/min per m^2 , cf. reference 20). Table III lists the values of $S_{IP(\text{clamp})}$ calculated these four possible ways for the five lowest-BMI subjects. (We were not able to do this for the more obese subjects because low-dose clamps were not performed on two of them, and in the others there was no measurable effect on R_d at the 15 mU/min per m^2 dose.) For the normal subjects, mean calculated $S_{IP(\text{clamp})}$ ranged from 2.69 to 2.92×10^{-2} $\text{dl}/(\text{min}$ per $\text{m}^2)$ per $\mu\text{U}/\text{ml}$, and there were no significant differences between the individual values for $S_{IP(\text{clamp})}$, for the four methods of calculation ($P > 0.50$ for all paired comparisons between groups in Table III).

In view of the similarities of $S_{IP(\text{clamp})}$ values calculated for normal subjects regardless of the insulin interval used, we chose to utilize the 0 to 40 mU/min per m^2 data for calculation of $S_{IP(\text{clamp})}$ since it could also be used for the obese subjects, and

Table III. Calculation of $S_{IP(\text{clamp})}$ * in Normal Subjects Using Different Sets of Clamp Data

Normal subject	Values ($\times 10^2 \text{ dl} \cdot \text{min}^{-1}$ per $\mu\text{U}/\text{ml}$) for different insulin infusion rates ($\text{mU}/\text{min} \cdot \text{m}^2$)			
	0-15	15-40	0-40	0-40 regression [†]
1	2.48	2.93	2.75	2.76
2	1.93	3.35	2.86	2.92
3	2.92	3.16	3.09	3.11
4	3.79	2.82	3.15	3.10
5	2.31	2.35	2.34	2.34
Mean±SE [‡]	2.69±0.32	2.92±0.17	2.84±0.14	2.85±0.14

* $S_{IP(\text{clamp})}$ is calculated as the change in R_d divided by the increment in insulin times the ambient glucose concentration [$\Delta R_d/(\Delta I \cdot G)$].

[†] Slope of linear regression for data at 0, 15 and 40 $\text{mU}/\text{m}^2 \cdot \text{min}$. Regression coefficient exceeded 0.99 for all regressions shown.

[‡] No significant difference was found between any pairs of values of $S_{IP(\text{clamp})}$ calculated by the four different techniques ($P > 0.5$, paired t test).

it was very similar to the value obtained using best-fit linear regression (Table III).

Mean $S_{IP(\text{clamp})}$ for all subjects was 1.87×10^{-2} dl/min per m^2 per $\mu\text{U}/\text{ml}$ (Table II); however there was a wide range [0.15 to 3.15 $\text{dl}/(\text{min}$ per $\text{m}^2)$ per $\mu\text{U}/\text{ml}$]. Apparently the range was related to the variability in adiposity. Fig. 1 shows the very strong correlation between BMI and $S_{IP(\text{clamp})}$ ($r = -0.97$, $S_{IP(\text{clamp})} = -0.156 \times \text{BMI} + 6.54$). This correlation could be influenced by age. However, a multiple correlation with age included gave virtually the same relationship between BMI and $S_{IP(\text{clamp})}$ ($S_{IP(\text{clamp})} = -0.159 \times \text{BMI} + 0.008 \times \text{age} + 6.33$), with a partial correlation coefficient between $S_{IP(\text{clamp})}$ and BMI of -0.97 , while




Figure 1. Relationship between insulin sensitivity index from the euglycemic glucose clamps and adiposity. $S_{IP(\text{clamp})}$ is defined as ($\Delta R_d/\Delta I \cdot G$), where ΔR_d is the change in R_d between basal and at steady state during insulin infusion at 40 mU/min per m^2 , ΔI is the increment in insulin, and G is the glucose concentration during the clamps (85 mg/dl).

that with age was only 0.30 and was not significant ($P > 0.05$). Thus, in this group of subjects differences in age do not affect the conclusion that as much as 95% of the variance in insulin sensitivity of this group can be accounted for by their body mass alone. Also, the data in Fig. 1 suggest that the dependence of sensitivity upon adiposity is linear and continuous, rather than decreasing abruptly as adiposity exceeds a "threshold" value.

In addition to the strong correlation with body mass, $S_{IP(\text{clamp})}$ was somewhat more weakly (but significantly) negatively correlated with basal insulin concentration ($r = -0.74$, $P < 0.02$).

FSIGT results. All subjects had a significant first-phase insulin response (Fig. 2, integrated insulin over basal, 0–10 min after glucose injection) which averaged 0.84 ± 0.13 (mU/ml) \times min, and which was independent of adiposity ($r = 0.23$, Table IV, NS). Tolbutamide, injected at 20 min, induced a large secondary peak in plasma insulin (Fig. 2). The integrated, 22–180 min above basal response after tolbutamide was 4.38 ± 1.44 (mU/




Figure 2. "Modified" frequently-sampled intravenous glucose tolerance test (9). Values on the ordinate ("basal") are the average of 3 fasting values. Dots represent averaged measured values for 10 subjects; solid line in lower panel represents minimal-model fit to the data. Glucose (0.3 g/kg) was injected over 1 min at $t = 0$; tolbutamide (300 mg in lean, 500 mg in obese) was injected as a bolus 20 min later. Note that first seven glucose values are not fit by the model because they are elevated by incomplete mixing in the extracellular fluid. Intersection of the model prediction with the ordinate (predicted value at $t = 0$ ignoring mixing phase) is G_0 , the concentration that would have been obtained if extracellular mixing were instantaneous. G_b is the average basal (preinjection) glucose concentration.

ml) \times min. In contrast to the first phase insulin response, tolbutamide-stimulated plasma insulin response increased with adiposity ($r = 0.88$ with BMI, $P < 0.001$). As discussed, this adiposity-related increment in insulin response could not have been caused by the different dose of tolbutamide in the more obese patients, since the dose per body weight was similar for leaner (BMI < 30 kg/m²) versus more obese (BMI > 30 kg/m²) subjects (see Methods).

Minimal model analysis, like the glucose clamp, revealed a substantial range of insulin sensitivity (Table IV). S_1 varied from 0.66×10^{-4} to 7.34×10^{-4} min⁻¹ per μ U/ml (mean $S_1 = 3.59 \pm 0.79 \times 10^{-4}$ min⁻¹ per μ U/ml). The present report is the first using the tolbutamide modified test in obese subjects, and the range of S_1 values is consistent with previous reports in normal and obese subjects in whom the previously used protocol (glucose alone) was employed (8, 12).

The strong dependence of insulin sensitivity upon adiposity demonstrated with clamp data (Fig. 1) was confirmed with the minimal model method (Fig. 3). As with the glucose clamp, there was a monotonic decline in sensitivity with increasing BMI. The correlation between model-based S_1 and BMI was -0.91 , (Table IV, $P < 0.001$), somewhat lower than the -0.97 obtained with the clamp. Also, the relationship between basal insulin and insulin sensitivity failed to achieve significance when the model-based S_1 was used ($r = -0.54$, $P = 0.10$).

Correlation between glucose clamp and FSIGT results. We found a strong correlation between the insulin sensitivity index measured from the glucose clamps, and that from minimal model analysis of the FSIGT (Fig. 4, $r = 0.89$; $P < 0.001$). Of additional interest is the regression equation between these independently measured parameters of insulin action: $S_1 = 1.94 S_{IP(\text{clamp})} - 0.03$.

The intercept (-0.03) is not different from 0.00 ($P > 0.9$). In fact, analysis of the data indicates that an upper 95% confidence limit for this intercept is less than 20% of the maximum S_1 value obtained. Thus, from this relatively small sample of patients we were not able to identify any factor, unrelated to insulin sensitivity itself which significantly biased the values of the measures obtained using the minimal model or the glucose clamp.

Equivalence of S_1 and $S_{IP(\text{clamp})}$. The fact that the relationship between S_1 and $S_{IP(\text{clamp})}$ passes through the origin provides the opportunity to determine if these measures are simply correlated with each other, or whether the clamp and minimal model methods are, in fact, measuring the same physiological parameter. To demonstrate equivalence, an additional criterion must be met: not only must the regression line pass through the origin, but in addition, the slope of the relationship between S_1 and $S_{IP(\text{clamp})}$ must be indistinguishable from 1.00.

At first glance it may seem that the relationship shown in Fig. 4 fails to satisfy the second criterion to demonstrate equivalence: the slope of the regression (1.94 ± 0.35 , slope \pm SE) is significantly different from 1.00 ($P < 0.05$). However, this apparent failure to satisfy the second criterion does not indicate inequality between S_1 and $S_{IP(\text{clamp})}$ because in Fig. 4 these parameters are not expressed in the same units; $S_{IP(\text{clamp})}$ is in units of dl/(min per m²) per μ U/ml; S_1 is in units of min⁻¹ per μ U/ml.

To examine whether the measures are equal (differences only due to random error) it is necessary to convert the measures to identical units. Both parameters can be expressed in terms of change in glucose clearance per change in plasma insulin concentration. To make the conversion for S_1 , it must be multiplied

Table IV. Results from the FSIGTs

Subject	Glucose dose	Integrated insulin over basal ((mU/ml) · min)		$S_I \times 10^4$
	g	0-10 min	22-180 min	$\text{min}^{-1} \text{ per } \mu\text{U/ml}$
1	15.3	0.647	0.490	6.32
2	19.5	1.215	0.981	6.79
3	19.8	0.794	1.765	4.88
4	22.8	0.439	1.247	7.34
5	24.0	1.005	3.884	2.46
6	29.1	0.178	2.697	1.98
7	36.0	1.310	3.461	2.71
8	36.3	1.331	10.883	0.87
9	27.0	0.434	4.159	1.94
10	42.0	1.008	14.227	0.66
Mean±SE	27.2±2.7	0.84±0.13	4.38±1.44	3.59±0.79
Correlation with BMI		0.23 (NS)	0.88 (P < 0.001)	-0.91 (P < 0.001)

by the distribution volume of glucose ($S_I \times V_D$, see Appendix). The minimal model assumes a single extracellular compartment of glucose distribution, and the volume of this compartment (V_D) is equal to the ratio of the glucose dose to the increment in plasma glucose. This increment is the difference between the post-injection glucose concentration and the basal glucose: $V_D = \text{Glucose dose}/(G_0 - G_b)$.

The postinjection glucose concentration (G_0) is found when the glucose data is fitted to the minimal model. The glucose data for the initial 8 min is not fitted by the model because during this interval glucose is mixing in the extracellular fluid (c.f., Fig. 2). When early mixing is ignored, the intercept of the model-predicted time course of plasma glucose with the ordinate is the predicted glucose concentration that would have been observed

if glucose had mixed instantaneously in the 1-compartment "glucose space." This value is G_0 .

The values of V_D for the 10 subjects are calculated in Table V. The volumes ranged between 95.6 and 222 dl in the 10 subjects, averaging 16.1% of body wt. This fraction is considerably less than the entire extracellular glucose space, which has previously been estimated to be 26% of body wt (21). In fact, the apparent glucose distribution volume was equal to 0.62 multiplied by the estimated total glucose distribution volume.




Figure 3. Relation between insulin sensitivity index from the minimal model (S_I) and adiposity. S_I is obtained from fitting the minimal model to the glucose data obtained during the modified FSIGT.




Figure 4. Linear relationship between sensitivity indices obtained from fitting the minimal model to the FSIGT (ordinate) or from the euglycemic glucose clamp data (abscissa). Note that S_I and $S_{IP(\text{clamp})}$ are expressed in different units. Although slope is different from 1.00 ($P < 0.05$), intercept (-0.003) is not different from 0.00 ($P > 0.90$).

Table V. Calculation of Distribution Volume from the Minimal Model Parameters

Subject	G_b mg/dl	G_0 mg/dl	V_D (dl) [Dose/($G_0 - G_b$)]	V_D % body wt	"pool fraction" % body weight/26
1	88	289	110.0	14.9	0.57
2	101	301	97.5	15.0	0.58
3	95	302	95.6	14.5	0.56
4	96	282	121.9	16.0	0.62
5	92	250	151.9	19.0	0.73
6	100	253	190.2	19.6	0.75
7	96	275	201.1	16.8	0.65
8	91	284	188.1	15.5	0.60
9	104	322	123.9	13.8	0.53
10	<u>108</u>	<u>297</u>	<u>222.0</u>	<u>15.9</u>	<u>0.61</u>
Mean±SE	97±2	279±9	150.2±46.7	16.1±0.6%	0.62±0.02

To convert $S_{IP(\text{clamp})}$ to change in clearance per unit change in plasma insulin it is only necessary to multiply it by body surface area (see Appendix). Thus, to demonstrate equivalence between S_I and $S_{IP(\text{clamp})}$ it is necessary to demonstrate that, on average, $S_I \times V_D = S_{IP(\text{clamp})} \times \text{surface area}$.

Table VI lists both S_I and $S_{IP(\text{clamp})}$, respectively corrected with distribution volume, or surface area. The product $S_I \times V_D$ varied from 0.089 to 0.015 dl/min per $\mu\text{U/ml}$ (mean = 0.046 ± 0.008). $S_{IP(\text{clamp})} \times \text{surface area}$ varied from 0.062 to 0.003 (mean 0.037 ± 0.007).

The relationship between S_I and $S_{IP(\text{clamp})}$ expressed in identical units is shown in Fig. 5. Again, the intercept is not different from 0.00 ($P > 0.40$). The slope of the relationship between these indices of insulin sensitivity was 1.05 ± 0.19 (SE). This slope is indistinguishable from 1.00 ($P > 0.7$). Thus, for the group as a whole, these two measures of insulin sensitivity, S_I and $S_{IP(\text{clamp})}$ apparently satisfied the criterion for equivalence discussed above.

Careful examination of Table VI reveals, however, that on a subject by subject basis there was a modest but significant tendency for $S_I \cdot V_D$ to exceed $S_{IP(\text{clamp})} \cdot \text{surface area}$ (SA) ($P < 0.05$ paired t test). One possible cause of this tendency for a greater sensitivity parameter with the model approach is a dif-

ference in definition of sensitivity by the two methods: whereas $S_{IP(\text{clamp})}$ measures the effect of insulin to increase total glucose disposal, S_I is a measure of the effect of insulin to increase total glucose economy, both by decreasing endogenous production and by enhancement of uptake. Thus, the small difference between these two measures ($S_I \cdot V_D$ averaged 0.009 dl/min per $\mu\text{U/ml}$ greater than $S_{IP(\text{clamp})} \cdot \text{SA}$) might be explained by the inclusion of inhibition of hepatic glucose production in the model-based measure.

During the euglycemic clamp, the exogenous glucose infusion must compensate for both the decrease in endogenous glucose production and the increase in glucose uptake. Therefore, the rate of glucose infusion is an indication of the total effect of the infused insulin on glucose economy. Thus, we recalculated insulin sensitivity from clamp data using glucose infusion (GINF) in place of R_d for the basal to 40 mU/m^2 per min clamp studies. The sensitivity index parameter based on infusion is $S_{I(\text{clamp})}$, defined as $(\Delta\text{GINF}/(\Delta I \cdot G))$. This latter parameter ($\times \text{SA}$) averaged 0.052 ± 0.007 dl/min per $\mu\text{U/ml}$ for the 10 subjects, slightly exceeding the model-based value of 0.046 ± 0.008 (Fig. 6). Thus, the subtle decrement in the insulin sensitivity measure seen when R_d was used was more than compensated for when total glucose

Table VI. Calculation of Similar Indices of Insulin Sensitivity from FSIGT and Glucose Clamp Results

Subject	S_I^* $\times 10^4$	V_D	$[S_I \cdot V_D]$	$S_{IP(\text{clamp})}$ $\times 10^2$	SA	$[S_{IP(\text{clamp})} \cdot \text{SA}]$
1	6.32	110.0	0.070	2.75	1.87	0.051
2	6.79	97.5	0.066	2.86	1.76	0.050
3	4.88	95.6	0.047	3.09	1.78	0.055
4	7.34	121.9	0.089	3.15	1.98	0.062
5	2.46	151.9	0.037	2.34	1.92	0.045
6	1.98	190.2	0.038	1.58	2.18	0.034
7	2.71	201.1	0.054	1.72	2.47	0.043
8	0.87	188.1	0.016	0.15	2.32	0.003
9	1.94	123.9	0.024	0.66	1.98	0.013
10	0.66	222.0	<u>0.015</u>	0.36	2.58	<u>0.009</u>
Mean±SE			0.046 ± 0.008			0.037 ± 0.007

* Units are defined as follows: S_I , min^{-1} per $\mu\text{U/ml}$; V_D , dl; $S_{IP(\text{clamp})}$, dl/($\text{min} \cdot \text{m}^2$) per $\mu\text{U/ml}$; SA (surface area), m^2 ; $S_I \cdot V_D$, and $(S_{IP(\text{clamp})} \cdot \text{SA})$ are in identical units of dl/min per $\mu\text{U/ml}$.




Figure 5. Relationship between sensitivity index measured from the FSIGT (ordinate) and the clamps (abscissa) transformed so that both parameters are expressed in identical units. S_I is multiplied by glucose distribution volume; $S_{IP(\text{clamp})}$ is multiplied by body surface area (see text and Appendix). The slope of the relationship is not different from unity ($P > 0.7$) and the intercept is indistinguishable from 0.00 ($P > 0.40$). Dashed line is line of unity slope, zero intercept.

infusion rate was substituted in the clamp-based index of insulin sensitivity. This result is consistent with the notion that the small decrease in $S_{IP(\text{clamp})} \cdot SA$ compared to $S_I \cdot V_D$ was due to the lack of inclusion of liver glucose production inherent in the R_d -based, clamp-derived sensitivity index $S_{IP(\text{clamp})}$.

The substitution of GINF for R_d did not change the equivalent relationship between the clamp based and model-based sensitivity indices. Slope of the relationship between $S_{I(\text{clamp})}$ and S_I was 0.93 (not different from 1.00, $P > 0.5$); the intercept was -0.003 (not different from 0.00, $P > 0.5$, data not shown).

Discussion

Insulin resistance is an important factor underlying the glucose intolerance observed in a variety of metabolic disorders. Among these conditions are some of major epidemiologic importance, such as aging, obesity, and NIDDM, as well as several less prevalent diseases (22–24). Given the benefits that accrue from a better understanding of these conditions, it follows that it is important to develop approaches to assess insulin sensitivity which entail minimum risk and difficulty, but which provide maximum quantitative information. The availability of such approaches has the potential for improved classification of metabolic illness, better prognosis, and earlier detection and intervention.

The euglycemic clamp technique, conceived by Andres et al. (6) and widely exploited by others (c.f. reference 5) remains the most direct approach to assessment of whole-body insulin sensitivity. Using the clamp one may determine a direct dose-response relationship between the steady state concentration of

insulin in plasma and the effect of insulin to suppress endogenous glucose production and enhance glucose uptake. However, as we and others have discussed elsewhere, even these data can be difficult to interpret if comparisons are made among glucose clamp results obtained at different plasma glucose and/or insulin levels (25).

The above considerations have encouraged us to examine alternative approaches to measuring insulin sensitivity. In particular, we have been searching for a method which circumvents some of the aspects of the clamp which have prevented its use outside the clinical research laboratory. The criteria we have attempted to fulfill include the following: (a) no special equipment requirements for the performance of the test, (b) a test that may be performed in an office rather than a laboratory setting (such a test could be used for field studies), (c) reduced labor requirements, and (d) minimization of risk. In addition, and possibly more important, we have desired a methodology for which (e) the attainment of steady state is not a necessity. Finally, it was hoped that the test would provide an accurate assessment of insulin sensitivity which was (within limits) independent of glycemia and insulinemia.

To strive to satisfy these aforementioned criteria we have made use of the digital computer to analyze the dynamics of plasma insulin and glucose observed following glucose injection. The injection of glucose is simple to perform, and virtually risk free. By implementation of the “minimal model” of insulin-dependent net glucose disappearance on the computer (5, 7–9), we have been able to describe the effect of changes in plasma insulin on the postinjection decline of plasma glucose. From the model parameters which emerge from the fitting procedure, we can calculate the S_I . This sensitivity parameter is a measure of the effect of an increment in plasma insulin to enhance the fractional net disappearance of glucose from an assumed single compartment of extracellular glucose distribution. There is evidence that within the physiological range this parameter is relatively independent of the levels of glycemia and insulinemia at which it is determined (12, 26).

The potential of the minimal model approach seemed to us to satisfy most of the requirements we had set down. However, Donner et al. recently reported a very weak correlation ($r = 0.44$) between insulin sensitivity from the minimal model analysis, and that observed on a group of subjects using the euglycemic clamp (10, 11). Given the demonstrated utility of the clamp, the Donner et al. reports seemed to demonstrate that the minimal model approach violated the accuracy criterion. If S_I were indeed an inaccurate index, such a result would severely limit the usefulness of the minimal model approach.

Recent results reported by Beard and his colleagues, in collaboration with some of us (12), have led to a potential explanation for the somewhat disappointing results of Donner et al. We showed that the correlation between the minimal model method and the euglycemic clamp could be considerably strengthened ($r = 0.83$) if the data used as a basis for calculating S_I were obtained not from a glucose injection alone, but from a “modified” FSIGT protocol in which tolbutamide was also injected 20 min after glucose. This modified protocol produced a significantly greater plasma insulin response than glucose alone, and a substantial portion of the insulin response occurred after the 0–8 min postglucose injection mixing period (27). Because the model requires a substantial effect of insulin after the initial glucose mixing period to calculate a precise measure of insulin sensitivity, addition of the tolbutamide to the injection protocol

caused a substantial increase in the correlation between model-based and clamp-based sensitivity (12). However, our earlier studies failed to address the issue of the accuracy of the S_I estimate: is S_I from the FSIGT simply proportional to clamp-determined insulin sensitivity, or is it in fact equivalent to the sensitivity parameter obtained from the clamp? Demonstrating equivalence represents a validation not only of the FSIGT-based S_I , but a validation of the minimal model as well.

The present results confirm a strong and highly significant correlation between the insulin sensitivity index measured by the two methods. In fact, in the present studies there was a tendency for the correlation to be higher than was previously found ($r = 0.89$ compared with 0.83); presumably this may be explained by the fact that in the present studies we used subjects of widely varying body mass index, and are thus able to compare S_I and $S_{IP(\text{clamp})}$ in obesity, while Beard used only normal-weight subjects. The increased variability of adiposity resulted in a wider range of S_I in the present studies (0.66 to $7.34 \times 10^{-4} \text{ min}^{-1} \text{ per } \mu\text{U/ml}$, an 11-fold difference). Assuming that a wider range in insulin sensitivity would be obtained with a greater variability of adiposity, a stronger correlation would be expected, based upon statistical principles (19).

Of particular interest was the negative relationship between insulin sensitivity and obesity in these studies as BMI increased above the normal range (Figs. 1 and 3). While we have insufficient data to determine whether adiposity will lead to relative insulin resistance within the normal limits of body mass index, apparently even mild obesity can have a measurable effect and possibly lead to the negative risk factors associated with diminished sensitivity to the hormone. Further, even after moderate obesity occurs, progression to more severe obesity leads to an additional, measurable decline in insulin action.

More significant than the strong correlation between $S_{IP(\text{clamp})}$ and S_I in the present studies are the following facts: first, that the correlation passed through the origin (0, 0); second, that when properly corrected for differences in units, the slope of the relationship was close to unity. In addition, when glucose infusion rate was used as a basis for calculating clamp-based sensitivity, mean values of sensitivity were very similar with both methods (0.046 versus $0.052 \text{ dl/min per } \mu\text{U/ml}$). These results provide strong evidence that the minimal model method and the euglycemic clamp are measuring the same physiological parameter, rather than reflecting different processes which happen to be related to each other. In addition, these results imply that there is no important factor, unrelated to insulin sensitivity, which systematically biases the measurement of either S_I or $S_{I(\text{clamp})}$. Stated in more general terms, these results demonstrated that (except for random error due to measurement and biological variation between successive measurements) $S_I = S_{IP(\text{clamp})}$, providing that both parameters are expressed in identical units.

It should be emphasized that for a correlation analysis to be valid, the parameters correlated with each other must be assessed completely independently, i.e., there must not be any common measured variable that contributes to the value of both parameters being correlated. This criterion applies to the variables correlated in Fig. 4 as well as in Fig. 5. Thus, S_I and $S_{IP(\text{clamp})}$ were determined on the same individual, but on different days using entirely independent methods. The independence criterion also applies to the unit-corrected variables correlated in Fig. 3 ($S_I \cdot V_D$ versus $S_{IP(\text{clamp})} \cdot SA$); no factor is common to both measurements. Parameters S_I and V_D are both calculated from the FSIGT alone; $S_{IP(\text{clamp})}$ is determined from the clamp alone, while surface area

is estimated from height and weight (28). If this important consideration of the independence of correlated parameters is not obeyed, the correlation coefficient between the different measures of insulin sensitivity could not be taken per se as evidence of equivalence of the two measures.

In the previous study of Beard et al. the regression line did not pass through the origin. A possible reason for the non-zero positive intercept in the earlier study was that sequential euglycemic clamps were performed on a single day, at two levels of insulin infusion. In contrast, in the present experiments the clamps were done at different rates of insulin infusion, on different days. Because the effect of insulin on glucose disposal is long lasting (29), in sequential infusion studies there may be a "memory effect," such that a previous insulin infusion could augment the glucose uptake during a following infusion. Insulin infusion at a low rate followed by a higher one could act to increase ΔR_d and therefore the value of $S_{I(\text{clamp})}$ relative to S_I , and this effect would be progressively more significant at higher insulin infusion rates. This putative memory effect might explain the apparent insulin-dependent bias of $S_{I(\text{clamp})}$ in the previous study.

One of the primary simplifications implemented in the model is that during the FSIGT, glucose distribution can be described by a single compartment representation, despite evidence for three-compartment distribution of labeled glucose moieties when sufficient time is allotted (30, 31). Apparently, since glucose is rapidly normalized during the FSIGT (as compared, for example, to the glucose clamp) little filling of the slow compartments takes place. That equivalent one-compartment representation is adequate to account for FSIGT dynamics is supported by our previous demonstration of single-exponential restitution of the blood glucose, following glucose injection, when the increase in insulin was prevented by somatostatin (32). Thus, during the FSIGT, the glucose distribution system can be represented by an equivalent one-compartment model, with a single distribution volume, V_D . Whereas it remains unknown what tissues in the body account for this equivalent single compartment, it remains, as Steele pointed out many years ago (33), a useful conceptual framework for describing glucose dynamics when a relatively short time frame is available for glucose distribution.

Particularly interesting in this regard are the calculated values for V_D (Table V) which were estimated by fitting the minimal model. This apparent volume of distribution, calculated from the increment in plasma glucose (corrected for extracellular mixing), averaged 16.1% of the body wt. This value represents 0.62 times the total glucose distribution space, previously estimated to equal 26% of the body wt (21). What is interesting about the 0.62 factor is that it is almost equal to the so-called "pool fraction" Steele and his colleagues proposed many years ago (16, 21, 32). Those investigators proposed that one could calculate the rate of glucose production during the non-steady state by assuming a single-compartment distribution volume equal to 65% of the total distribution volume, when insufficient time was available for glucose equilibration into the entire three-compartment extracellular volume. Their conclusion was validated in the dog under limited conditions by Radziuk and Vranic (34).

The striking equivalence of the apparent distribution volume of the minimal model to the previously validated pool fraction suggests that for the short time periods and limited glucose loads, the single-compartment assumption with the pool fraction sim-

plification is adequate to represent glucose kinetics. In addition, prediction of the previously validated one-compartment volume can be considered an independent validation of the minimal model.

The ability of the modeling process to yield a measure of the single compartment equivalent glucose V_D in individual subjects (Table V) raises the possibility that V_D itself, estimated from the minimal model fit, could be used in the Steele relation, rather than the "population" value of $0.65 \times 26\%$ body wt, as is usually done (34). Independent studies will have to be done to determine if using individualized estimates of the pool fraction from the minimal model provides a more accurate assessment of glucose turnover rates from the Steele relationship than using the assumed pool fraction, 0.65.

Of course, we observed some variation in the relation between S_I and $S_{IP(\text{clamp})}$ (i.e., individual points did not lie exactly on the line of equality). What cannot be determined from the present study are the factors that contribute to this variability: how much is due to day-to-day variation in insulin sensitivity itself, how much to imprecision in the clamp measurement, and how much to imprecision in the minimal model analysis. The fact that the correlation was not improved markedly by substituting glucose infusion for R_d in the calculation of clamp-based sensitivity indicates that the variance was not due to failure to include liver inhibition in $S_{IP(\text{clamp})}$. Actual reproducibility determinations will require future studies of repetitive measures of sensitivity in the same individuals, using the two methods.

Despite the overall equivalence between sensitivity from the clamp and the model, we did find, on a paired basis, a marginally significant tendency for the sensitivity to be higher with the FSIGT than with the clamps, when the values were normalized to identical units (Table VI, Fig. 6). A possible explanation for this is that there is a difference between the definitions of insulin




Figure 6. Comparison of three expressions of the insulin sensitivity index in the 10 subjects. All parameters are in units of dl/min per $\mu\text{U/ml}$. $S_{IP(\text{clamp})}$ is calculated from euglycemic clamps using R_d only [$S_{IP(\text{clamp})} = \Delta R_d / (\Delta I \cdot G)$]. S_I is from the minimal model (p_3/p_2 , see Methods), while $S_{I(\text{clamp})}$ is calculated from clamp data using glucose infusion data only [$S_{I(\text{clamp})} = \Delta \text{GINF} / (\Delta I \cdot G)$]. GINF is the increment in glucose infusion at steady-state, and it is equal to $(\Delta R_d - \Delta \text{HGO})$.

sensitivity using the clamps, versus minimal model-analyzed FSIGT data. With clamps, we defined sensitivity in terms of the action of insulin to augment glucose utilization (R_d). In the FSIGT, however, model-derived sensitivity is defined in terms of the ability of insulin to both augment glucose utilization and to inhibit hepatic glucose output. Thus, it is the total effect of insulin on the net glucose economy of the body which is represented in S_I . Therefore, it would not be surprising if, on a subject-by-subject basis, the higher sensitivity found from the FSIGT compared to the glucose clamps may have been due to the inclusion of the liver effect in the definition of insulin sensitivity.

The hypothetical role of inhibition of hepatic glucose output (HGO) to the higher sensitivity measured by FSIGT compared to $S_{IP(\text{clamp})}$ is diagrammed in Fig. 7. The average increment in sensitivity of FSIGT measurement over the R_d based measurement was $0.009 \text{ dl/min per } \mu\text{U per ml}$ (Table VI), and this increment was approximately the same for normal and obese subjects (Fig. 7).

The hypothesis that the increment in the model-based compared to the R_d -based sensitivity is due to inclusion of HGO inhibition in the former, leads to two predictions.

First, the increment of the FSIGT-based over the R_d -based sensitivity can be accounted for by some fraction of the basal rate of HGO, because insulin can do no more than completely inhibit HGO regardless of the concentration achieved during the FSIGT. The increment in the model-based compared to the R_d -based sensitivity can be expressed in terms comparable with glucose turnover by multiplying by the clamp glucose concentration (85 mg/dl) and the increment in insulin due to the 40 $\text{mU/m}^2 \text{ per min}$ insulin infusion (average, 98 $\mu\text{U/ml}$), and dividing by the surface area. So transformed, the $0.009 \text{ dl/min per } \mu\text{U/ml}$ difference is equivalent to $36 \text{ mg/min per m}^2$. The latter




Figure 7. Mean values of three expressions of the insulin sensitivity index (see legend to Fig. 6) for subjects with BMI < 30 or BMI > 30 kg/m^2 . It is hypothesized (see Discussion) that the increment in S_I or $S_{I(\text{clamp})}$ over $S_{IP(\text{clamp})}$ is due to the fact that the former two indices include insulin inhibition of HGO while the latter does not.

value is less than the basal glucose production (Table II). Therefore, the extent to which insulin sensitivity measured with the FSIGT exceeds that based upon R_d is consistent with half the basal hepatic glucose output being inhibited during the FSIGT protocol.

Second, the concept that the increment in sensitivity of the FSIGT-based value over the R_d -based value is due to partial suppression of HGO during the FSIGT is consistent with the fact that when total glucose infusion (R_d increase + HGO decrease) was used as a basis for expressing sensitivity, the value obtained exceeded the FSIGT-based value by 0.006 dl/min per $\mu\text{U/ml}$ (24 mg/min per m^2). We expect sensitivity to be higher when infusion rate was the basis for the calculation because the liver was 70–100% suppressed during the 40 mU/min per m^2 glucose clamps.

Assuming that the inhibition of HGO is responsible for the larger estimate of insulin sensitivity when the FSIGT is used, compared to R_d -based glucose clamps, we can reach certain conclusions regarding the contribution of the insulin-mediated inhibition of HGO, compared to insulin stimulation of glucose uptake. First, in normal individuals only about 17% of S_I is due to insulin inhibition of HGO; the remainder is due to insulin increasing R_d (Fig. 7). Therefore, in such individuals it will matter little whether the liver effect is included in the overall sensitivity determination. Second, the contribution of HGO inhibition to sensitivity was similar in obese individuals and normals (0.008 versus 0.009 dl/min per $\mu\text{U/ml}$). Therefore, it would make little difference for comparing insulin sensitivity between normal and obese individuals whether the FSIGT or the R_d -based glucose clamp was used. In fact, the absolute difference in sensitivities would be virtually the same (FSIGT: $0.062 - 0.029 = 0.033$ dl/min per $\mu\text{U/ml}$; R_d -based clamp values: $0.053 - 0.021 = 0.032$ dl/min per $\mu\text{U/ml}$). Therefore, it appears to be justified to use the parameter S_I for assessing insulin action in individuals of differing sensitivity to the hormone, even though S_I includes within it the effects of insulin to inhibit endogenous glucose production and to augment glucose utilization.

While the present data is consistent with the idea that the slightly higher index calculated from the FSIGT is due to liver suppression, it is still possible that there is an alternative reason. One possibility is that steady state glucose utilization was not achieved in our clamp experiments, despite 180 min of insulin infusion. This artifact could result in an underestimate of $S_{IP(\text{clamp})}$. Other possibilities include unaccounted for loss of glucose via renal excretion which would lead to overestimation of V_D . The latter possibility seems unlikely since < 3% of injected glucose is cleared during an intravenous glucose tolerance test (35, 36), and renal clearance would contribute not to S_I , but the term independent of the insulin response, S_G (32). However, whether our supposition is correct that the small differential is due to inclusion of liver suppression in S_I , but not $S_{IP(\text{clamp})}$, or whether the differential is due to some other cause remains to be tested experimentally.

In conclusion, the present data demonstrate that minimal model analysis of the frequently sampled intravenous glucose tolerance test yields a measure of insulin sensitivity which is equivalent to the same parameter measured by the euglycemic glucose clamp. The results imply that the measure is dominated by extrahepatic effects of the hormone. Previous poor correlation between these methods was apparently due to suboptimal dynamic testing protocols, rather than inadequacy of the minimal model itself. In addition, the FSIGT is less labor intensive and

requires less specialized equipment than the glucose clamp, and the FSIGT yields some information about B-cell function (8). Therefore, the present results indicate that the minimal model method is potentially useful for measuring insulin sensitivity in longitudinal or cross-sectional epidemiologic studies of insulin resistance in nondiabetic individuals, when use of the glucose clamp is not feasible for economic or practical reasons. Of course, it will be necessary to extend validation studies to a wider variety of conditions and to larger populations if general use of the methodology is to be recommended.

Appendix

While they both reflect insulin sensitivity, S_I and $S_{IP(\text{clamp})}$ are not directly comparable because they are expressed in different units (S_I in min^{-1} per $\mu\text{U/ml}$ and $S_{IP(\text{clamp})}$ in dl/(min per m^2) per $\mu\text{U/ml}$). To convert them to a common unit it is necessary to use conversion factors which emerge from the method used to estimate them: S_I should be converted using parameters estimated for the minimal model approach; $S_{IP(\text{clamp})}$ conversion must use factors associated with the euglycemic glucose clamp.

The fundamental difference between S_I and $S_{IP(\text{clamp})}$ as used in the present work is that the former expresses the effect of insulin to increase net fractional disappearance of glucose from the extracellular "glucose space" (i.e., rate of net glucose disappearance divided by amount of glucose in the pool).² The latter represents the effect of insulin to enhance glucose clearance (rate of glucose uptake divided by plasma glucose concentration) per unit body surface area. Thus, these two parameters are normalized to different measures of body "size"; the former to the volume of distribution of glucose of the minimal model itself, the latter to body surface area. However, both parameters can be easily converted to a common index of insulin sensitivity: the effect of a unitary change in insulin to cause a given increment in glucose clearance.³ For purposes of discussion, let us define the parameter S_c , which represents the insulin sensitivity index in units of increment in glucose clearance per unit increment in plasma insulin, expressed in units of deciliters per minute per microunit per milliliter.

Glucose clamp. To reiterate, $S_{IP(\text{clamp})}$ is defined as $(\Delta R_d / (\Delta I \times G))$, where R_d is expressed in mg/min per unit surface area of the body, I is in $\mu\text{U/ml}$, and G is in mg/dl. The units of $S_{IP(\text{clamp})}$ are dl/(min per m^2) per $\mu\text{U/ml}$, or clearance per unit surface area divided by insulin concentration. To convert $S_{IP(\text{clamp})}$ to S_c , we simply multiply by the surface area of the individual expressed in m^2 . Then, for the euglycemic clamp, S_c will be expressed in dl/min per $\mu\text{U/ml}$:

$$S_c = S_{IP(\text{clamp})} \times \text{surface area.} \quad (\text{A1})$$

Minimal model. The fractional disappearance rate as used in S_I is the net glucose disappearance rate divided by the glucose "pool" size, where the pool size is the mass of glucose in the single glucose compartment of the minimal model itself. Thus, if we define V_D as the assumed single compartment distribution space with glucose concentration G , the net disappearance rate is given as the fractional rate multiplied by $V_D \cdot G$. However, to convert the net rate to glucose clearance it has to be divided by G . Thus, G drops out, and to convert S_I to S_c we simply

2. "Net" glucose disappearance refers to the sum of any decrease in glucose production plus increase in glucose uptake, either of which will act to lower the plasma glucose concentration.

3. Actually, for S_I this is given in terms of net glucose clearance; for $S_{IP(\text{clamp})}$ this definition is made in terms of absolute glucose clearance (the insulin-induced decrement in HGO is not included). This distinction results in a small but significant difference between S_I and $S_{IP(\text{clamp})}$ in a given individual (see Discussion). Also, it is important to note that although glucose clearance itself decreases significantly at physiological hyperglycemia (ref. 24 and Table VI of ref. 5) the effect of insulin to enhance glucose clearance (the basis of S_I) does not appear to diminish in the physiological range of hyperglycemia (cf. Fig. 28 of ref. 5).

multiply S_I by V_D expressed in dl. Then S_c will be expressed in dl/min per $\mu\text{U/ml}$:

$$S_c = S_I \times V_D. \quad (\text{A2})$$

Summary. Thus, by expressing parameters $S_{IP(\text{clamp})}$ and S_I according to equations A1 and A2, respectively, they are converted to the common parameter S_c , expressed in dl/min per $\mu\text{U/ml}$. We may demonstrate equality, then, if

$$S_I \times V_D = S_{IP(\text{clamp})} \times \text{surface area}. \quad (\text{A3})$$

Note that the quantities of the left hand side of equation A3 are measured independently of those on the right hand side. This excludes bias in the statistical comparison of the two methods for measuring S_c .

Acknowledgments

We are grateful to Marilyn Ader for her aid in producing the manuscript.

This work was supported by grants from the National Institutes of Health to Drs. Olefsky (AM-33649) and Bergman (AM-29867), and by the Medical Research Service of the Veterans Administration Medical Center, San Diego, CA.

References

1. Reaven, G. M., J. Moore, and M. Greenfield. 1983. Quantification of insulin secretion and in vivo insulin action in non-obese and moderately obese individuals with normal glucose tolerance. *Diabetes*. 32: 600-604.
2. DeFronzo, R. A. 1979. Glucose intolerance and aging. Evidence for tissue insensitivity to insulin. *J. Clin. Invest.* 28:1095-1101.
3. Ginsberg, H., G. Kimmerling, J. M. Olefsky, and G. M. Reaven. 1975. Demonstration of insulin resistance in untreated adult onset diabetic subjects with fasting hyperglycemia. *J. Clin. Invest.* 55:454-461.
4. Shen, S.-W., G. M. Reaven, and J. W. Farquhar. 1970. Comparison of impedance to insulin-mediated glucose uptake in normal subjects and in subjects with latent diabetes. *J. Clin. Invest.* 49:2151-2160.
5. Bergman, R. N., D. T. Finegood, and M. Ader. 1985. Assessment of insulin sensitivity in vivo. *Endocrine Rev.* 6:45-86.
6. Andres, R., R. Swerdloff, T. Pozefsky, and D. Coleman. 1966. Manual feedback technique for the control of blood glucose concentration. In *Automation in Analytical Chemistry*, J. R. Skeggs, editor. Mediad Inc., New York. 486.
7. Bergman, R. N., Y. Z. Ider, C. R. Bowden, and C. Cobelli. 1979. Quantitative estimation of insulin sensitivity. *Am. J. Physiol.* 236:E667-E677.
8. Bergman, R. N., L. S. Phillips, and C. Cobelli. 1981. Physiologic evaluation of factors controlling glucose tolerance in man. Measurement of insulin sensitivity and beta-cell sensitivity from the response to intravenous glucose. *J. Clin. Invest.* 68:1456-1467.
9. Bergman, R. N., J. Beard, and M. Chen. 1986. The minimal modeling method. Assessment of insulin sensitivity and B-cell function in vivo. In *Methods in Clinical Diabetes Research*. J. Larner and S. Pohl, editors. Wiley International, New York. pp. 13-20.
10. Donner, C. C., E. Frazee, Y.-D. I. Chen, C. B. Hollenbeck, J. E. Foley, and G. M. Reaven. 1985. Presentation of a new method for specific measurement of in vivo insulin-stimulated glucose disposal in humans: comparison of this approach with the insulin clamp and minimal model techniques. *J. Clin. Endocrinol. Metab.* 60:723-726.
11. Foley, J. E., Y.-D. I. Chen, C. K. Lardinois, C. B. Hollenbeck, G. C. Lin, and G. M. Reaven. 1985. Estimates of in vivo insulin action in humans: comparison of the insulin clamp and the minimal model techniques. *Horm. Metab. Res.* 17:406-409.
12. Beard, J. C., R. N. Bergman, W. K. Ward, J. B. Halter, and D. Porte, Jr. 1986. Study of the insulin sensitivity index in man: correlation between clamp-derived and ivgtt-derived values. *Diabetes*. 35:362-369.
13. Kolterman, O. G., L. J. Insel, M. Saekow, and J. M. Olefsky. 1980. Mechanisms of insulin resistance in human obesity. Evidence for receptor and postreceptor defects. *J. Clin. Invest.* 65:1272-1284.
14. Youn, J., Y. Yang, and R. N. Bergman. 1986. Assessment of insulin sensitivity from the IVGTT: improvement of accuracy using modified protocols. *Clin. Res.* 34:67a. (Abstr.)
15. Finegood, D. T., and R. N. Bergman. 1983. Optimal segments: a method for smoothing tracer data to calculate metabolic fluxes. *Am. J. Physiol.* 244:E472-479.
16. Steele, R. 1959. Influences of glucose loading and of injected insulin on hepatic glucose output. *Ann. NY Acad. Sci.* 82:420-430.
17. Desbuquois, B., and G. D. Auerbach. 1971. Use of polyethylene glycol to separate free and antibody bound peptide hormones in radioimmunoassay. *J. Clin. Endocrinol. Metab.* 33:732-738.
18. Pacini, G., and R. N. Bergman. 1986. MINMOD: A computer program to calculate insulin sensitivity and pancreatic responsiveness from the frequently sampled intravenous glucose tolerance test. *Computer Methods Progr. Biomed.* 23:113-122.
19. Sokal, R. R., and F. J. Rohlf. 1969. *Biometry*. In *The Principles and Practice of Statistics in Biological Research*. W. H. Freeman and Co., San Francisco, CA.
20. Kolterman, O. G., G. M. Reaven, and J. M. Olefsky. 1979. Relationship between in vivo insulin resistance and decreased insulin receptors in obese man. *J. Clin. Endocrinol. Metab.* 48:487-494.
21. Steele, R., J. S. Wall, R. C. de Bodo, and N. Altszuler. 1956. Measurement of size and turnover rate of body glucose pool by the isotope dilution method. *Am. J. Physiol.* 187:15-24.
22. Ginsberg, H., J. M. Olefsky, and G. M. Reaven. 1975. Evaluation of insulin resistance in patients with primary hyperparathyroidism. *Proc. Soc. Exp. Biol. Med.* 148:942-945.
23. Bar, R. S., W. R. Levis, M. M. Rechler, L. C. Harrison, C. Siebert, J. Podskalny, J. Roth, and M. Muggeo. 1978. Extreme insulin resistance in ataxia telangiectasia. *N. Engl. J. Med.* 298:1164-1171.
24. Felber, J. P., and E. Jequier. 1982. Glucose storage deficiency as a cause of insulin resistance in obese hyperinsulinemic diabetes. *Int. J. Obesity*. 6:131-135.
25. Gottesman, I., L. Mandarino, and J. Gerich. 1984. Use of glucose uptake and glucose clearance for the evaluation of insulin action in vivo. *Diabetes*. 33:184-191.
26. Beard, J., J. Best, W. K. Ward, and R. N. Bergman. 1982. A glucose-level independent measurement of insulin sensitivity. *Diabetes*. 31:59A. (Abstr.)
27. Finegood, D. T., R. Watanabe, and R. N. Bergman. 1984. Validation of estimation by optimal segments of the end of extracellular mixing of injected glucose. *Fed. Proc.* 43:411A. (Abstr.)
28. Ganong, W. F. 1981. *Review of Medical Physiology*. Lange Medical Publications, Los Altos, CA. 221.
29. Gray, R. S., J. A. Scarlett, J. Griffin, J. M. Olefsky, and O. G. Kolterman. 1982. In vivo deactivation of peripheral, hepatic and pancreatic insulin action in man. *Diabetes*. 31:929-936.
30. Sherwin, R. S., K. J. Kramer, J. D. Tobin, P. A. Insel, J. E. Liljenquist, M. Berman, and R. Andres. 1974. A model of the kinetics of insulin in man. *J. Clin. Invest.* 53:1481-1492.
31. Cobelli, C., G. Federspil, G. Pacini, A. Salvan, and C. Scandarelli. 1982. An integrated mathematical model of the dynamics of blood glucose and its hormonal control. *Math. Biosci.* 58:27-60.
32. Ader, M., G. Pacini, Y. J. Yang, and R. N. Bergman. 1985. Importance of glucose per se to intravenous glucose tolerance: comparison of the minimal model prediction with direct measurements. *Diabetes*. 34:1092-1103.
33. Steele, R. 1971. *Tracer Probes in Steady-State Systems*. Charles C Thomas, Springfield, IL.
34. Radziuk, J., K. H. Norwich, and M. Vranic. 1978. Experimental validation of measurements of glucose turnover in nonsteady state. *Am. J. Physiol.* 3:E84-E93.
35. Amatuzio, D. S., F. L. Stutzman, M. J. Vanderbilt, and S. Nesbitt. 1953. Interpretation of the rapid intravenous glucose tolerance test in normal individuals and in mild diabetes mellitus. *J. Clin. Invest.* 32: 428-435.
36. Ikkos, D., and R. Luft. 1957. On the intravenous glucose tolerance test. *Acta Endocrinol.* 25:312-334.